Press Releases

Auris Medical Announces Acquisition of Orphan Drug Designation and Secures Rights to In-License Additional Patents Related to Betahistine

12/06/18

Auris Medical Announces Results of Pre-IND Meeting With FDA For AM-201 Program in Olanzapine-Induced Weight Gain

11/20/18

Auris Medical Reports Third Quarter 2018 Financial Results and Provides Business Update

11/15/18

Auris Medical to Report Third Quarter 2018 Financial Results and Provide Business Update on Thursday, November 15, 2018

11/08/18

Auris Medical Announces Positive Results From Second Phase 1 Clinical Trial With Intranasal Betahistine

10/17/18

Auris Medical to provide update on intranasal betahistine program on Wednesday, October 17, 2018

10/12/18

Auris Medical Receives FDA Guidance at Type C Meeting for AM-111 in the Treatment of Sudden Sensorineural Hearing Loss

08/30/18

Auris Medical Reports Second Quarter 2018 Financial Results and Provides Business Update

08/15/18

Auris Medical to Report Second Quarter 2018 Financial Results and Provide Business and Update on Wednesday, August 15, 2018

08/09/18

Auris Medical Prices $7 Million Public Offering

07/12/18

Auris Medical Announces Publication Confirming Dose-Dependent Effects of Betahistine and Relationship to Bioavailability in Cat Model of Acute Vertigo

07/03/18

Auris Medical to Host Key Opinion Leader Call Focused on AM-201 Program for Treating Major Side Effects of Antipsychotics on June 11, 2018

05/30/18

Auris Medical Provides Business and Strategy Update and Reports First Quarter 2018 Financial Results

05/15/18

Auris Medical to Report First Quarter 2018 Financial Results and Provide Business and Strategy Update on Tuesday, May 15, 2018

05/14/18

Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111

05/07/18

Auris Medical Announces Publication Related to AM-111 in Peer-Reviewed Scientific Journal

05/04/18

Auris Medical Announces Early Repayment of Part of its Loan Facility

04/09/18

Auris Regains Compliance with Nasdaq's Minimum Bid Price Requirement

03/29/18

Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results

03/22/18

Auris Medical Provides Business Update

03/13/18

Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen® Tinnitus Program on March 5, 2018

02/26/18

Auris Medical Announces Extraordinary General Meeting of Shareholders

02/09/18

Auris Medical Reports New Data Highlighting Superior Bioavailability of AM-125 Compared to Oral Betahistine

02/07/18

Auris Medical Announces Pricing of $5.5 Million Registered Direct Offering

01/29/18

Auris Medical Provides Update on AM-111 Development Program

01/04/18